Georgakarakos Nikolaos D, Sullivan Paul, Dowler Jonathan
From the *Institute of Ophthalmology, University College London, London, United Kingdom; and †Moorfields Eye Hospital, London, United Kingdom.
Retin Cases Brief Rep. 2010 Fall;4(4):294-6. doi: 10.1097/ICB.0b013e3181aff491.
Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) used in the treatment of a variety of ocular conditions. It is known to exert an inhibitory effect on new vessels but has not previously been documented to affect mature vascular beds.
The authors present an uncommon side effect of intravitreal bevacizumab, consisting of inflammation and transient nonperfusion of conjunctival, episcleral, and scleral vessels surrounding the injection site.
Possible mechanisms of this complication, including ischemia and inflammation, are considered.
The possibility of this complication should be recognized by clinicians treating patients with intravitreal bevacizumab, and measures should be taken to limit drug reflux at the injection site.
贝伐单抗是一种针对血管内皮生长因子（VEGF）的单克隆抗体，用于治疗多种眼部疾病。已知它对新血管有抑制作用，但此前尚无文献记载其会影响成熟血管床。
作者报告了玻璃体内注射贝伐单抗一种不常见的副作用，表现为注射部位周围结膜、巩膜上和巩膜血管的炎症和短暂无灌注。
考虑了这种并发症的可能机制，包括缺血和炎症。
接受玻璃体内注射贝伐单抗治疗的患者，临床医生应认识到这种并发症的可能性，并应采取措施限制注射部位的药物反流。
